Anti-TB Drugs

What Anti-TB drug us being described? MOA: Inhibits mycolic acid synthesis. Bactericidal

Isoniazid

What Anti-TB drug us being described? Uses: Tuberculosis (active, latent, prophylaxis)

Isoniazid

What Anti-TB drug us being described? Adverse Effect: Hepatitis, Neurotoxicity, Drug induced Lupus

Isoniazid

What Anti-TB drug us being described? Nicotinic acid derivative

Isoniazid

What Anti-TB drug us being described? MOA: Inhibits DNA-dependent RNA Polymerase -> inhibits RNA production. Bactericidal

Rifampicin, Rifabutin, Rifapentine, Rifamixin

What Anti-TB drug us being described? Uses: Tuberculosis (active, latent, prophylaxis), Leprosy, Atypical mycobacterium, Prophylaxis of meningococcal

Rifampicin, Rifabutin, Rifapentine, Rifamixin

What Anti-TB drug us being described? Adverse Effects: Red-Orange body fluids, light chain proteinuria, skin rash, thrombocytopenia

Rifampicin, Rifabutin, Rifapentine, Rifamixin

What Anti-TB drug us being described? Rifamycins

Rifampicin, Rifabutin, Rifapentine, Rifamixin

What Anti-TB drug us being described? MOA: Converted to active pyrazinoic acid under acidic in conditions. Pyrazinoic acid disrupts mycobacterial cell membrane metabolism and transport functions

Pyrazinamide

What Anti-TB drug us being described? Uses: Tuberculosis (active)

Pyrazinamide

What Anti-TB drug us being described? Adverse Effects: Most hepatotoxic drug among anti TB regimen, non gouty polyarthralgia

Pyrazinamide

What Anti-TB drug us being described? Pyrazine derivatives

Pyrazinamide

What Anti-TB drug us being described? MOA: Inhibits arabinosyl transferases involved in the synthesis of arabinogalactan in mycobacterial cell wall. Bacteriostati

Ethambutol

What Anti-TB drug us being described? Uses: Tuberculosis (active), atypical mycobacterial infections

Ethambutol

What Anti-TB drug us being described? Adverse Effects: Visual disturbances (decrease visual acuity, red-green color blindness, retrobulbar neuritis, retinal damage) headache, confusion, hyperuricemia

Ethambutol

What Anti-TB drug us being described? Butanol derivative

Ethambutol

What Anti-TB drug us being described? MOA: Inhibit protein synthesis by binding to S12 ribosomal subunit. bactericidal

Streptomycin

What Anti-TB drug us being described? Uses: Tuberculosis (drug-resistant strains) Tularemia, bubonic plague, Brucellosis

Streptomycin

What Anti-TB drug us being described? Adverse Effects: Hypersensitivity, Nephrotoxicity, Ototoxicity, Neuromuscular blockade and Teratogen (congenital deafness)

Streptomycin

What Anti-TB drug us being described? Aminoglycosine

Streptomycin

When is 2 months of HRZE (Isoniazid, Rifampin, Pyrazinamide, Ethambutol). prescribed

During the Initial phases of New smear- or culture-positive cases or New culture-negative cases

When is Continuation Phase: 4 months of HR (Isoniazid, Rifampin) prescribed?

During the Initial phases of New smear- or culture-positive cases or New culture-negative cases

When is 2 months of HRE (Isoniazid, Rifampin, Ethambutol) prescribed

During the Initial phases of Pregnancy, Pyrazinamide (Z) is typically avoided in pregnancy due to limited safety data.

When is Continuation Phase: 7 months of HR. prescribed

During the Initial phases of Pregnancy, Pyrazinamide (Z) is typically avoided in pregnancy due to limited safety data.

When is Tailored based on rapid drug susceptibility testing prescribed

Relapses and treatment default/Failures

When is Throughout (6 months) of RZEQ (Rifampin, Pyrazinamide, Ethambutol, Quinolone) prescribed

Resistance (or intolerance) to H (Isoniazid)

When is 2 months of HRE (Isoniazid, Rifampin, Ethambutol) and Continuation Phase: 7 months of HR prescribed

Intolerance to Z (Pyrazinamide)